RE: Valirx13 Nov 2019 07:24
The actual RNS
APPOINTMENT OF JOINT BROKER
London, UK., 13 November 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce the appointment of Allenby Capital Limited as the Company's joint broker, with immediate effect.
Dr Satu Vainikka, CEO of ValiRx Plc, commented:
"I very much look forward to working with the team at Allenby Capital and to ValiRx benefiting from the broker's life-science and healthcare research capabilities to promote and facilitate understanding and transparency regarding the progress of our clinical trials".
*** ENDS ***